Clinical Studies of Safety and Effectiveness of Orphan Products

The summary for the Clinical Studies of Safety and Effectiveness of Orphan Products grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the Other Agency, which is the U.S. government agency offering this grant.
Clinical Studies of Safety and Effectiveness of Orphan Products: Please note that there is only one receipt date for FY 2009 and one receipt date for FY 2010. 1. Background OPD was created to identify and promote the development of orphan products. Orphan products are drugs, biologics, medical devices, and foods for medical purposes that are indicated for a rare disease or condition (that is, one with a prevalence, not incidence, of fewer than 200,000 people in the United States). Diagnostic tests and vaccines will qualify only if the U.S. population of intended use is fewer than 200,000 people a year. Additional information about OPD is available on FDAs Web site at www.fda.gov/orphan. 2. Program Research Goals The goal of FDAs OPD grant program is to support the clinical development of products for use in rare diseases or conditions where no current therapy exists or where the product will improve the existing therapy. FDA provides grants for clinical studies on safety and/or effectiveness that will either result in, or substantially contribute to, market approval of these products. Applicants must include in the applications Background and Significance section documentation to support the estimated prevalence of the orphan disease or condition and an explanation of how the proposed study will either help gain product approval or provide essential data needed for product development. All funded studies are subject to the requirements of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 331 et seq.), regulations issued under it, and applicable Department of Health and Human Services (HHS) statutes and regulations. Inclusion of Women And Minorities in Clinical Research Applicants for PHS clinical research grants are encouraged to include minorities and women in study populations so research findings can be of benefit to all people at risk of the disease or condition under study. It is recommended that applicants place special emphasis on including minorities and women in studies of diseases, disorders, and conditions that disproportionately affect them. This policy applies to research subjects of all ages. If women or minorities are excluded or poorly represented in clinical research, the applicant should provide a clear and compelling rationale that shows inclusion is inappropriate. Inclusion of Children as Participants in Clinical Research. FDA regulations at 21 CFR part 50, subpart D contain additional requirements that must be met by IRBs reviewing clinical investigations regulated by FDA and involving children as subjects. FDA is part of HHS; accordingly, the research project grants under this program are supported by HHS, and HHS regulations at 45 CFR part 46, subpart D also apply to research involving children as subjects. Standards for Privacy of Individually Identifiable Health Information HHS issued final modification to the Standards for Privacy of Individually Identifiable Health Information, the Privacy Rule, on August 14, 2002. The Privacy Rule is a federal regulation under the Health Insurance Portability and Accountability Act (HIPAA) of 1996 that governs the protection of individually identifiable health information, and is administered and enforced by the HHS Office for Civil Rights (OCR). PHS is committed to achieving the health promotion and disease prevention objectives of Healthy People 2010, a PHS-led national activity for setting priority areas. This Funding Opportunity Announcement is related to one or more of the priority areas. Potential applicants may obtain a copy of Healthy People 2010 at http:// www.health.gov/healthypeople. Smoke-Free Workplace The PHS strongly encourages all grant recipients to provide a smoke-free workplace and discourage the use of all tobacco products. In addition, Public Law 103-227, the Pro-Children Act of 1994, prohibits smoking in certain facilities (or in some cases, any portion of a facility) in which regular or routine education, library, day care, health care, or early childhood development services are provided to children. This is consistent with the PHS mission to protect and advance the physical and mental health of the American people.
Federal Grant Title: Clinical Studies of Safety and Effectiveness of Orphan Products
Federal Agency Name: Other Agency
Grant Categories: Science and Technology Health
Type of Opportunity: Discretionary
Funding Opportunity Number: FD08-001
Type of Funding: Grant
CFDA Numbers: 93.103
CFDA Descriptions: Food and Drug Administration_Research
Current Application Deadline: No deadline provided
Original Application Deadline: Feb 06, 2008 All Applications must be received by
Posted Date: Jul 06, 2007
Creation Date: Jul 06, 2007
Archive Date: Feb 15, 2008
Total Program Funding: $4,200,000
Maximum Federal Grant Award: $400,000
Minimum Federal Grant Award: $200,000
Expected Number of Awards: 12
Cost Sharing or Matching: No
Applicants Eligible for this Grant
Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility
The grants are available to any foreign or domestic, public or private, for-profit or nonprofit entity (including State and local units of government). Federal agencies that are not part of the Department of Health and Human Services (HHS) may apply. Agencies that are part of HHS may not apply. For profit entities must commit to excluding fees or profit in their request for support to receive grant awards. Organizations that engage in lobbying activities, as described in section 501(c)(4) of the Internal Revenue Code of 1968, are not eligible to receive grant awards. An application that has received two prior disapprovals is not eligible to apply.
Link to Full Grant Announcement
Information not provided
Grant Announcement Contact
Marc Pitts
Senior Grants Management Specialist
Phone 301-827-7162 [email protected] [email protected]
Similar Government Grants
Clinical Trials Addressing Unmet Needs of Rare Neurodegenerative Diseases (R01) Clinical T...
Single Source Cooperative Agreement to Support HPAI H5N1 Research at Cornell University (U...
Animal and Veterinary Innovation Centers (U18)
Cooperative Agreement to Support the Illinois Institute of Technology's Institute for Food...
Minor Use Minor Species Development of Drugs (R01)
Support for Small Scientific Conference Grant Program
Cooperative Agreement to Support the World Health Organization (WHO) International Program...
FDA State Food Safety Task Force Conference
More Grants from the Other Agency
This is a test opporturtunity. Please DO NOT submit.
TEST-TEST-TEST-02-05-10
Test

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2007-2024 FederalGrants.com